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Transfusions are the mainstay of supportive therapy in patients with aplastic anemia (AA) and may lead to anti-
HLA alloimmunization, thereby also increasing the risk for donor-specific antibodies in the setting of HLA-mis-
matched transplantation. Historically, AA patients were thought to be at particularly high risk for HLA alloimmu-
nization. In past decades, blood product manufacturing (leukoreduction) and HLA antibody testing have
improved significantly by single antigen bead (SAB) technology. It is currently unknown how those developments
have impacted HLA alloimmunization and treatment outcome in patients with AA. We retrospectively investi-
gated 54 AA patients treated by immunosuppressive therapy or allogeneic hematopoietic cell transplantation
after the introduction of the SAB assay at our center. We compared the HLA antibody results to a historical AA
cohort (n = 26), treated before introduction of leukoreduced blood products from 1975 to 1995. HLA alloimmuni-
zation was detected in 43 of 54 (80%) recently treated patients. Past pregnancy, female gender, disease severity,
age, and a history of other transfusions were significantly associated with a larger number or higher intensity
(mean fluorescence intensity) of HLA antibodies. Treatment outcome including bleeding episodes, response to
treatment, engraftment, graft-versus-host disease, and overall survival was not associated with HLA alloimmuni-
zation. In the historical cohort a significantly higher number of HLA antibodies (P < .01) with a higher mean fluo-
rescent intensity (P < .01) was observed. HLA alloimmunization remains frequent in AA tested by current
techniques, but it has significantly decreased since prior decades and does not affect treatment outcome.
 2021 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
© 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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/licenses/by-nc-nd/4.0/)Aplastic anemia (AA) is a rare disease defined as bicytope-
nia or pancytopenia with hypocellular bone marrow and is
classically treated by intensive immunosuppressive therapy
(IST) or allogeneic hematopoietic stem cell transplantation
(HCT). Transfusion support with RBC and platelets are the
mainstay of supportive care [1]. However, transfusions, as well
as previous pregnancies and transplantation, may trigger anti-
bodies against non-self HLA [26]. HLA antibodies in turn can
cause platelet transfusion refractoriness and are associatedwith graft failure after HCT, eventually impacting therapy
response and clinical outcome [7,8].
Immune dysregulation is known to play a major role in the
pathogenesis of AA [9], and AA patients may be particularly at
risk for HLA alloimmunization considering that Holohan et al.
[10] already documented in 1981 a higher frequency of alloim-
munization in AA compared to other hematological malignancies
and solid tumors. Most of the older literature dates back before
the general introduction of leukoreduction of blood products sig-
nificantly decreasing HLA alloimmunization [11]. In addition,
detection of HLA antibodies was with cell-based assays, which
has been replaced by the solid-phase single antigen bead (SAB)
technology in the past years. SAB technology allows the detection
of HLA antibodies with a high sensitivity, allowing a detailed
characterization of HLA antibodies [2,5,6,12]. There is limited
Table 1





Recent cohort 54 100
Females 21 39
Historical cohort 26 100
Females 10 38
Age at diagnosis, median (IQR)
Recent cohort 48 years (22-64 years)
Historical cohort 20 years (14-28 years)
















Acquired AA 50 93
Inherited AA 4 7
Fanconi anemia 3 6




Very severe 17 32





IST + HCT 12 22
HCT details
Donor
Matched related 20 80
Matched unrelated (at least 10/10) 0 0
Mismatched 5 20











MTX and/or cyclosporine 21 88
MMF/cyclosporine +/MTX 3 12
(continued)
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No Incompatibility 13 52
Minor Incompatibility 7 28







IQR indicates interquartile range; RBC, red blood cell concentrate; PC, platelet concentrate; AA, aplastic anemia; IST, intensive immunosuppression; GvHD, graft-ver-
sus-host disease; HCT, hematopoietic stem cell transplantation; Cy, cyclophosphamide; Flu, fludarabine; Bu, busulfan; MTX, methotrexate; MMF, mycophenolate
mofetil; PBSC, peripheral blood stem cells; BM, bone marrow; D/R, donor/recipient.
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measured by SAB assays in AA. Therefore this study aims to ana-
lyze HLA alloimmunization in consecutive AA patients treated by
IST or HCT at our center since the introduction of this technique
in 2008. Likewise, we aim to compare the results to a historical
validation cohort treated from 1975 to 1995, at a decade when
leukoreduced blood products had not been introduced for which
samples had been stored. We also intend to identify associated
risk factors for HLA alloimmunization and possible effects on
treatment and patient outcome.
METHODS
Study population
All consecutive AA patients treated with HCT or IST at the University Hos-
pital and the Children’s University Hospital, Basel, Switzerland, between
2008 and 2018 were included in this retrospective study (n = 54). Patients
without HLA antibody testing were excluded.
As a validation cohort we tested sera for HLA antibodies using current
techniques of 26 historical patients, treated at the University Hospital Basel
from 1975 to 1995 for whom stored samples were available. The samples
were collected before start of the first treatment and stored at 75°C.
Data on baseline characteristics, diagnosis, treatment, HLA typing, and anti-
body testing results and outcomes were collected from patients’ history and
added to a chart for further statistical evaluation [13]. For the historical cohort,
the exact number of transfusions and pregnancies was not available. The local
ethic committees approved the study (EKNZ Project-ID 2019-01614).Table 2
HLA Antibodies




HLA antibody testing before first therapy, median (range)
Number of patients
Number of HLA antibodies
HLA antibody testing during/after first therapy, median (range)
Number of patients
Number of HLA antibodies
Number of days from diagnosis till first HLA antibody testing, median (range)
Number of HLA antibodies in females, median (range)
With pregnancy
Without pregnancyTreatment
Themajority of patients underwent HCTwith bonemarrow from amatched
related donor (MRD), less frequently from a 9/10 mismatched or haploidentical
donor. The FCA regimen (fludarabine, cyclophosphamide (Cy), ATG) was used as
conditioning in the majority of cases; less frequently CyBuATG, the FCC regimen
(fludarabine, Cy, alemtuzumab), or reduced-intensity conditioning schemes
were given. Cyclosporine/methotrexate was the graft-versus-host disease
(GvHD) prophylaxis in most of the patients (Table 1).
IST consisted of cyclosporine and equine antithymocyte globulin (hATG,
ATGAM; Pfizer, New York, NY), during a period when hATG was unavailable
rabbit ATG was used. Since 2016 patients received eltrombopag when
included in a prospective trial. All patients were transfused with g-irradiated
(30 Gy), leucocyte-depleted RBC since 1999, and pathogen-reduced platelets
(Intercept) since 2011. RBC were transfused at a hemoglobin level below 80
g/L and platelet concentrates at a platelet count less than 10 g/L or 20 g/L in
case of fever, mucositis, or GVHD, respectively. Patients received HLA-
matched or antigen-negative platelet units if available in case of platelet
refractoriness [14]. Standard supportive care also included infectious disease
prophylaxis and broad-spectrum intravenous antibiotics as published else-
where.
Outcome
Treatment response to IST was classified according to NIH criteria at the
most recent follow-up [15,16]. Neutrophil engraftment after HCT was defined
as the first of 3 consecutive days of an absolute neutrophil count (ANC)
exceeding 0.5 g/L and platelet engraftment as a platelet count exceeding 20
g/L without transfusion for 7 days. Acute and chronic GvHD were diagnosed













Associations With HLA Alloimmunization in the Study Cohort: Regression Results
Variable Number of antibodies* Average MFIy Highest MFIy
IRR P 95% CI exp (b) P 95% CI exp (b) P 95% CI
Age 0.98 .000 0.96-0.99 1.01 .174 1.00-1.03 1.01 .512 0.99-1.03
Gender (ref = male)
Female 1.77 .158 0.80-3.94 2.70 .003 1.41-5.17 4.65 .001 1.87-11.56
Pregnancy (ref = no)
Yes 4.26 .002 1.72-10.55 1.89 .022 1.10-3.25 1.60 .167 0.82-3.10
Disease severity (ref = severe)
Very severe 2.58 .002 1.42-4.68 0.59 .145 0.29-1.20 0.87 .808 0.28-2.70
RBC transfusionsz 1.00 .943 0.98 1.01 .046 1.00-1.02 1.01 .170 1.00-1.03
PLT transfusionsz 1.01 .527 0.98-1.02 1.00 .845 0.99-1.02 1.00 .947 0.98-1.02
Daysx 1.00 .162 1.00-1.00 1.00 .813 1.00-1.00 1.00 .621 1.00-1.00
Constant 11.15 .000 4.92 567.11 .000 207.4-1550.4 1080.64 .000 225.0-5189.5
Alpha 1.65
MFI indicates mean fluorescent intensity; IRR, incident rate ratio; exp(b), exponentiated coefficient; 95% CI, 95% confidence interval; P, Probability
* Negative binomial regression with robust standard errors.
y Generalized linear model of the Gaussian family with log link and robust standard errors.
z Number of transfusions.
x Days between HLA antibody testing and diagnosis.
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centers, data on all blood counts and confounding factors (fever, sepsis, etc.)
at the time of transfusion were not available. We therefore assessed response
to platelet transfusions by using bleeding as a clinical outcome parameter
instead of the corrected count increment, which is based on the platelet
increment after 2 consecutive transfusions. Bleeding was classified according
to the World Health Organization (WHO) bleeding grades.
HLA antibody testing
Serum samples were centrifuged for 10 minutes at 2558g (4000 rpm) and
stored at 30°C until further testing. HLA antibody Class I- and Class II-test-
ing was performed by using the One Lambda LABScreen Single Antigen class I
(LS1A04, Lot no. 11 or Lot no. 12) and LABScreen Single Antigen class II
(LS2A01, Lot no. 13) with microbead based assay technique (Luminex, Austin,
TX). Anti-HLA antibodies with a mean fluorescent intensity (MFI) >500 are
considered to be positive in our center. This cutoff can be supported by aFigure 1. (A) Number of HLA antibodies according to age and gender. (B) Association b
antibodies in women with or without pregnancies. (D) Number of HLA antibodies in parecent study evaluating different definitions for a positive SAB result in solid
organ transplantation [19]. For the purpose of this study, we either consid-
ered an MFI >500 as positive in most cases or the highest MFI of a bead
coated with a self-HLA. The testing was performed after a median of 73 days
(interquartile range [IQR] 30-317) after diagnosis and before therapy with
IST or HCT.
High resolution HLA typing
High-resolution HLA-A/B/C/DRB1 typing of donors and patients was per-
formed by either SSO DNA-typing (LABType HD; One Lambda, West Hills, CA)
or sequencing-based typing (Histogenetics LLC, Ossining, NY) [20] for the
study cohort.
Statistical analysis
The first available HLA antibody test result in each patient was used to
assess the number of HLA antibodies (class I and II), as well as the averageetween pregnancy and number of HLA antibodies over age. (C) Number of HLA
tients with or without red cell alloantibodies.
Figure 2. Association between MFI and RBC transfusions.
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errors were applied to assess the association between the number of HLA
antibodies, gender, age at diagnosis, disease severity (severe, very severe),
pregnancy (no/yes), and the number of previous RBC transfusions and plate-
let transfusions in the study cohort. We adjusted for the number of days
between HLA antibody testing and diagnosis. Similarly, generalized linear
models of the Gaussian family with a log link and robust standard errors
were used to assess the association between average and highest MFI and
the respective covariates. All statistical analyses are described in detail in the
supplemental material. All calculations were made with Stata Version 15.1
(StataCorp, College Station, TX).RESULTS
Baseline characteristics of the study cohort
The study cohort consisted of 54 AA patients, including
more males (33 [61%]) than females (21 [39%]). The median
age at diagnosis was 48 years (IQR 22-64). The majority of
patients were diagnosed with acquired AA (50 [93%]); in 4
(7%) patients the diagnosis of inherited AA was made. Most
patients suffered from severe AA (34 [63%]), less frequently
from very severe AA (VSAA) (17 [32%]) and non-severeFigure 3. (A) Number of HLA antibodies and (B) Average(3 [6%]). Patients were treated after a median of 55 (IQR 24-
141) days after diagnosis. Data on therapy response and com-
plications is listed in the supplemental material. The median
transfusion number before the first HLA antibody testing was
5 (IQR 0.3-11) RBC and 6 (IQR 1-13) platelet concentrates. The
median number of days from diagnosis until the first HLA anti-
body testing was 73 (IQR 30-317). Further baseline details are
listed in Table 1.HLA alloimmunization of the study cohort
Number of HLA antibodies
HLA antibodies class I or II were detected in 43 of 54 (80%)
patients. Thirty-eight (70%) patients were tested for HLA anti-
bodies before the first treatment; in these patients a median of
8 (IQR 1-27) HLA antibodies were found. In patients with HLA
antibody testing during or after treatment showed a median
number of HLA antibodies of 7 (IQR 2-22) (Table 2). In the
adjusted model (Table 3), past pregnancy (Incidence rate ratio
(IRR) = 4.26; 95% confidence interval [CI]: 1.72-10.55; P = .002)
and very severe disease (IRR = 2.58; 95% CI: 1.42=4.68;
P = .002) were associated with a higher number of HLA anti-
bodies, whereas older age (IRR = 0.98; 95% CI: 0.96-0.99;
P = .000) was associated with a lower number of HLA antibod-
ies. Further analysis revealed that the latter was particularly
the case in men (Figure 1A). Gender, the number of previous
RBC and platelet transfusions, and the number of days
between diagnosis and HLA antibody testing were not statisti-
cally associated with HLA antibody number. When analyzing
separately for HLA antibody class I and II, the covariates—
except age and past pregnancy—were not statistically signifi-
cant (results not shown). Interestingly, VSAA patients did not
receive more RBC and platelet transfusions before HLA anti-
body testing. The median number of antibodies was higher in
previous pregnant females than in nulliparous females (18
(IQR 6-68) versus 8 (IQR 4-17), Figure 1C). In a subgroup of
patients (n=7), we could not show a difference regarding HLAMFI in historical cohort compared to study cohort.
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sus directly before HCT (Figure 1c in supplemental material).
Characteristics of HLA antibodies
The median MFI was 1975 (IQR 874-5385) in the study
cohort. The median MFI was 4365 (IQR 1705-7357) in previous
pregnant females and 1192 (IQR 720-4725) in nulliparous
females. In the adjusted model (Table 3), female gender (exp
(b) = 2.70; 95% CI: 1.41-5.17; P = .003), past pregnancy (exp
(b) = 1.89; 95% CI: 1.10-3.25; P = .022), and the number of pre-
vious RBC transfusions (exp(b) = 1.01; 95% CI: 1.00-1.02;
P = .046) were associated with higher average MFI (Figure 2).
The remaining covariates (age at diagnosis, previous platelet
transfusions, disease severity, and the number of days
between diagnosis and HLA antibody testing) were not signifi-
cant. One RBC transfusion was associated with an average pre-
dicted MFI increase of 22 (95% CI: 0.06-43), whereas
pregnancy led to a predicted increase of 2209 in average MFI
(95% CI: 523-3895). Female gender per se was associated with
a predicted increase of 1898 in average MFI (95%CI: 630-
3167). Furthermore, adjusted highest MFI (Table 3) were sub-
stantially higher in women (exp(b) = 4.65; 95% CI: 1.87-11.56;
P = .001). Remaining covariates were not significant. The pre-
dicted highest MFI in women and men was 9062 (95% CI:
5532-12591) and 1949 (445-3455), respectively.
HLA antibody specificities
Overall, 209 different HLA antibodies specificities were
detected (95 class I, 114 class II). HLA antibodies against HLA-A
and HLA-B were most frequent. In the majority of the patients,
antibodies of both class I and II (26%) were detected; 9 patients
(22%) had only class I, and 7 patients (17%) only class II. The
number of antibody specificities in females was much higher
than in male patients (569 antibodies in 17 females versus 249
antibodies in 24 males). In 5 patients undergoing mismatched
HCT there were no donor-specific antibodies (DSA).
HLA antibodies and treatment outcome
There was no significant difference in the number (P = .487
and P = .384) or MFI (P = .560 and P = .836) of HLA antibodies
between patients with or without relevant bleeding (WHO grade
 2) during and after treatment. In the setting of HCT neither
neutrophil nor platelet engraftment was significantly associated
with the number (Sub-distribution hazard-ratio (SHR) = 1.01;
95% CI: 0.99-1.04; P = .284 and SHR = 1.03; 95% CI: 0.99-1.06;
P = .052) or MFI (SHR = 1.00; 95% CI: 0.99-1.00; P =.729 and
SHR = 1.00; 95% CI: 0.99-1.00; P = .110) of HLA antibodies. Acute
GvHD and chronic GvHD were not significantly associated with
the number (P = .604 and P = .565) and MFI (P = .664, P = .253) of
HLA antibodies. In the total cohort (P = .767 and P = .565), as well
when assessing patients with IST (P = .793 and P = .366) versus
HCT (P = .978) separately, we found that therapy response was
not influenced by the number andMFI of HLA antibodies. Neither
HLA antibody number nor MFI affected survival in the first year
after diagnosis, when comparing the groups divided by median
HLA antibody number (P = .967) or median MFI (P = .999).
Historical validation cohort
Baseline characteristics of the historical and study cohort
were not significantly different with regard to gender
(P = .935) and time between diagnosis and first HLA antibody
testing (P = .444). However, patients in the historical cohort
were significantly younger (P< .001) with a median age of
21 years at diagnosis (IQR: 17-28). Adjusting for age at diagno-
sis, gender, and the number of days between diagnosis andHLA testing, patients in the historical cohort nonetheless had
significantly more HLA antibodies (IRR = 4.05; 95% CI: 2.04-
8.05; P = .000) with a higher average (exp(b) = 2.08, 95% CI:
1.24-3.50; P = .006) and maximum (coef(b) = 2.21; 95% CI:
1.20-4.08; P = .011) MFI as compared to patients in the study
cohort. The average number of predicted HLA antibodies was
66 (95% CI: 32-101) (Figure 3A). Similarly, average MFI and
maximum MFI were higher in the historical cohort with pre-
dicted average MFI of 4582 (95% CI: 2933-6231) and predicted
maximumMFI of 13273 (95% CI: 8588-17958) (Figure 3B).
DISCUSSION
HLA alloimmunization is a well-known phenomenon in AA
patients [10,15,16,21], but data on the exact frequency and
outcome of HLA alloimmunization tested by sensitive SAB
assays and after introduction of leukoreduced blood products
is still limited.
Our results demonstrate that HLA alloimmunization
remains frequent in AA tested by sensitive SAB assays, but it
has substantially decreased in the past decades, not only quan-
titatively but also in terms of MFI of HLA antibodies. This sig-
nificant reduction of sensitization over the past years is best
explained by transfusing leukoreduced blood products since
1999. In line with this, a pilot study in the United Kingdom first
investigated the use of leukoreduced blood products in AA
patients in 1997, comparing the results to a historical cohort
without leukoreduction, also demonstrating a major reduction
in HLA alloimmunization from 50% to 12% [22]. In this study
HLA antibodies were tested by cell-based assays, probably
underestimating the degree of alloimmunization. A smaller
Egyptian study also confirmed the positive effect of leukore-
duction in AA, reporting on a decreased rate from 40% to 0%
[1]. Data on HLA antibodies tested by SAB assays in AA are
scarce, but in a subgroup of patients from the NIH (n = 32) HLA
alloimmunization was reported at a rate of 28% [23], which is
quite low in comparison to our cohort. However, the study did
not clearly state whether testing was performed for both HLA
class I and II antibodies, and focused on a very selected patient
group receiving granulocyte transfusions for severe infection.
In a recent Chinese study with pediatric AA HCT recipients, the
incidence of anti-HLA antibodies was also remarkably high
(54.9%) tested by SAB assays for class I and II [24].
Overall, HLA alloimmunization remains a challenge in AA
patients despite universal leukoreduction of blood products
and the use of more sensitive tests, confirming a strong ratio-
nale for performing standardized HLA antibody testing in this
patient group. The frequency of screening for HLA antibodies
remains nevertheless unclear and has to be balanced against
the clinical usefulness, because our results simultaneously
demonstrate that the clinical outcome such as response to
treatment, bleeding, and survival was not affected by HLA
alloimmunization. From patients on the waiting list for kidney
transplantation, we know that HLA alloimmunization, once
detected, is relatively stable over time if no immunizing events
occur, suggesting that the frequency of HLA antibody testing
should be chosen individually rather than defining a specific
interval for all patients [25]. This strategy might be difficult to
transfer to AA, because the majority of AA patients are transfu-
sion dependent at the time of diagnosis.
In the large multicenter Leukocyte Antibody Prevalence
Study, the transfused volunteer blood donors did not appear
to have a significantly higher prevalence of HLA antibodies
than their nontransfused counterparts [26]. This is in line with
our results, suggesting that blood transfusions could be less
important for HLA alloimmunization. However, the MFI was
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(Figure 2, Table 3), emphasizing the importance of this well-
known immunizing event. In the context of transfusion, the
rate of HLA alloimmunization can also be influenced by racial
disparity between patients and blood donors. However, our
patients and blood donors were predominantly of Caucasian
origin.
In the setting of mismatched transplantation HLA antibodies
are crucial because they can act as DSA, leading potentially to
graft failure [27]. In our study cohort only 5 patients receivedmis-
matched HCT without detectable DSA. However, we regard DSA
currently as less challenging in AA because MRD transplantation
is most often performed in AA patients because of its superior
outcome in comparison to mismatched unrelated donor or hap-
loidentical HCT [28,29]. However, in patients without available
MRD, the risk for HLA antibodies acting as a DSA should be taken
seriously, emphasizing the importance of screening for HLA anti-
bodies in this disease entity and preventing HLA alloimmuniza-
tion in the first place. In this context, our finding of a higher HLA-
antibody number in young male patients (Figure 1a) might be of
particular importance because this can affect the outcome of mis-
matched transplantation in this young patient group, potentially
leading to adaptions of conditioning and desensitization. One
hypothesis for this phenomenon could be that younger individu-
als are exposed to more infectious pathogens, which could trigger
the formation of HLA antibodies [30]. Unfortunately, infections
were underreported in our cohort to answer this question.
HLA alloimmunization is also a risk factor for platelet
refractoriness [11], which exposes patients to a higher risk for
bleeding, but also challenges clinical management and
requires significant resources of the providing transfusion cen-
ters. In our cohort interestingly HLA alloimmunization was not
associated with more relevant bleeding events (WHO grade 
2). However, bleeding is influenced by various factors (eg,
comedication, comorbidities, age), and therefore the results
should be interpreted cautiously. Our center transfuses HLA-
matched platelet units in HLA-alloimmunized patients, possi-
bly explaining the low bleeding rate in our cohort. This is a
costly procedure [31] and cannot be followed in every center.
Hence, strategies to prevent alloimmunization in AA patients
still have a priority.
Besides the classical risk factors (transfusion, pregnancy)
very severe disease (VSAA) turned out to be a significant risk
factor for HLA alloimmunization in our AA cohort, irrespective
of the number of previous transfusions. This might point
toward a higher immunogenicity in this subgroup, corrobo-
rated by our finding that AA patients with known RBC alloim-
munization also had significantly more HLA antibodies in
bivariate analysis (Figure 1D). Holohan et al. [10] already
described in 1981 a greater risk for HLA alloimmunization in
AA than hematological neoplasia, and the cause for this associ-
ation has not been elucidated so far. Acquired AA (93% of our
patients) is thought to be an immune-mediated disease [32],
and it is widely accepted that primarily cellular immunity—
particularly cytotoxic T-cells—play a critical role [32], whereas
the impact of humoral immunity in AA remains unclear. An
increased incidence of autoantibodies of uncertain clinical rel-
evance was documented by screening of serum samples of AA
patients [33,34], and the authors hypothesized that the target
autoantigens recognized by CD4 or CD8 T cells might produce
a humoral response (ie, autoantibody production). However,
abnormalities of B-cells and upregulation of antibody produc-
tion has not been described as a key attribute of AA, leaving
our finding of a higher rate of alloimmunization in AA com-
pared to other malignant hematological diseases unanswered.Looking at other nonmalignant blood disorders, also high rates
of HLA alloimmunization are reported in hemoglobinopathies,
depending on previous transfusion numbers and leukocyte
reduction. Friedman et al. [35] documented HLA antibodies in
85% of sickle cell disease patients with at least 50 non-leuko-
cyte-reduced RBC transfusions, 48% of patients with fewer
than 50 transfusions, and none of the 14 untransfused patients
[35]. Nickel et al. [36] found in 29% of patients with sickle cell
disease HLA antibodies receiving leukocyte reduced blood
products. A similar rate of HLA alloimmunization (31%) is
reported in patients with thalassemia [37]. Considering that all
patients in our cohort have received leukocyte-reduced RBC
transfusions, AA patients are possibly more affected by HLA
alloimmunization than patients with hemoglobinopathy.
Overall, both nonmalignant entities seem to show a high rate
of HLA alloimmunization, which might point to the immune-
and inflammation-mediated pathways in both diseases.
Evolving data from the immunogenetic field demonstrated
that specific HLA variants (eg, HLA-A*33:03; HLA-A*68:01,
HLA-B*40:02, HLA-B*14:02, HLA-DRB1*15:01) are associated
with an increased risk of AA [9]. We could not demonstrate
that these HLA variants correlated to the HLA antibody specif-
icities in our cohort; therefore, we cannot conclude that spe-
cific alleles are more frequently targeted by antibody
formation.
Finally, several limitations of the study merit consideration.
First, the relatively small number of patients and the retro-
spective design might have predisposed to selection bias and
residual confounding. We could not assess transfusion number
and pregnancy rate in the historical cohort because this data
was not available. In 30% of patients HLA antibody testing was
performed during or after treatment. Therefore test results
could have been influenced by therapeutic agents, especially
ATG and intravenous immunoglobulins, which are known to
contain anti-human HLA antibodies and can partly be detected
by anti-human IgG [30]. False-positive results can also occur
because of exposure to neo-epitopes and unspecific binding of
serummatrix components [38].CONCLUSION
HLA alloimmunization remains frequent in patients with
AA tested by current techniques but has significantly
decreased in recent decades. Pregnancy and disease severity
are the main risk factors for HLA alloimmunization in AA,
whereby the number of transfusions seems to be less impor-
tant recently. Overall, treatment and patient outcome are not
affected by HLA alloimmunization, but given increases in mis-
matched HCT, HLA antibodies might play an important role as
DSA in the future. Larger-scale prospective studies are needed
to identify additional risk factors and underlying causes of HLA
alloimmunization in AA, ultimately preventing HLA alloimmu-
nization in AA patients at greatest risk.ACKNOWLEDGMENTS
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